Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adavosertib + cytarabine
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous, Intrathecal
01
Overview
Adavosertib (AZD1775) + cytarabine (AraC) is a combination therapy consisting of a WEE1 kinase inhibitor and a nucleoside analog. Adavosertib is a potent and selective ATP-competitive small-molecule inhibitor of WEE1 kinase, while cytarabine is a conventional chemotherapeutic agent that damages DNA. The combination demonstrates synergistic anti-leukemic effects by enhancing DNA damage, abrogating S-phase arrest, and promoting apoptosis rather than cell cycle arrest. This combination shows activity independent of TP53 mutation status, making it potentially valuable for high-risk leukemias with poor prognosis genetic alterations.
- Brand names
- Cytosar-UDepoCytTarabine PFS
- Other names
- adavosertib + cytarabineWEE1 inhibitor + cytarabine
02
Targets
WEE2 (Wee1-like protein kinase 2)WEE1 (WEE1 G2 checkpoint kinase)DNADNA polymerase family
Beyond the preview
Go deeper on adavosertib + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adavosertib + cytarabine.